Acorda Therapeutics, Inc. (ACOR) shares are down 1.46% to $36.35 in recent trading following the drugmaker’s fourth quarter earnings results.
The Ardsley, New York-based company reported earnings of $0.46 per share on revenues of $117.9 million, up 27.3% from a year ago. Analysts were expecting EPS of $0.42 on revenues of $103.7 million.
For the year, the company reported GAAP net income of $17.7 million, or $0.42 per share. Revenue was reported as $401.5 million. Acorda said is sees full-year revenue in the range of $405 million to $420 million.
On valuation measures, Acorda Therapeutics Inc. shares, which currently have an average 3-month trading volume of 620,334 shares, trade at a trailing-12 P/E of 66.10, a forward P/E of 726.80 and a P/E to growth ratio of 1.88. The median Wall Street price target on the name is $44.00 with a high target of $65.00. Currently ticker has 3 ‘Buy’ endorsements, compared to 6 ’Holds’ and no ‘Sell’.
Profitability-wise, ACOR has a t-12 profit and operating margin of 6.26% and 13.66%, respectively. The $1.50B market cap company reported $766.44M in cash vs. $289.13M in debt in its most recent quarter.
ACOR currently prints a one year return of about 20% and a year-to-date loss of 9.74%.
The chart below shows where the equity has traded over the last 52 weeks.
Acorda Therapeutics Inc. is a biopharmaceutical company that develops therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The firm was founded in 1995 and is headquartered in Ardsley, New York.